ERYtech Pharma

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbe Triple Negative Breast Cancer	Phase 2 / Phase 3	2019-06-13
Completed	Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Pancreatic Adenocarcinoma	Phase 3	2018-09-15
Completed	Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Pancreatic Adenocarcinoma Metastatic	Phase 2	2014-07-01
Terminated	L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma	Phase 1	2013-10-01
Completed	GRASPA Treatment for Patients With Acute Myeloblastic Leukemia Acute Myeloid Leukemia	Phase 2	2013-02-01
Completed	GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse	Phase 2 / Phase 3	2009-12-01
Completed	Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Pancreatic Cancer	Phase 1	2009-11-01
Completed	Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With Fi Acute Lymphoblastic Leukemia	Phase 2	2009-04-01
Completed	Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic L Acute Lymphoblastic Leukemia	Phase 1 / Phase 2	2006-01-01
No Longer Available	Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Pol Acute Lymphoblastic Leukemia	—	—